Harrow Health, Inc.

NASDAQ:HROW

Drug Manufacturers - Specialty & Generic

Healthcare
$32.16 +0.29%

+$0.12 today

Market cap
$1.21B
Beta
0.28
P/E (TTM)
-104.7
EPS (TTM)
-$0.40
52W Low $28.54High $54.85

Volume 0.87M

Average 0.75M

HROW Debt Repayment

Cash used to repay borrowings during the period.

Harrow Health, Inc.NASDAQ: HROW

Debt Repayment · Q1 FY2026 · quarter ended Mar 2026

Debt repayment outflow grows to $48.89M

Q1 FY2026 debt repayment was $48.89M, compared with $0 a year earlier. Trailing-twelve-month debt repayment was $60.73M. Over 3 fiscal years it compounded at -28.0% a year.

Context

  • Debt repayment amounted to 4.3% of revenue in FY2025, down 10.6 pp from a year earlier.
  • Debt repayment increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly debt repayment holds near $48.89M or moves back toward the trailing-twelve-month quarterly average of $15.18M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$48.89M+101947.9% QoQ
Last fiscal yearDec 2025
$11.84M-60.2% YoY
LTMMar 2026
$60.73M+103.9% YoY
Debt Repayment past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-60.2%——
3-year CAGR-28.0%——
5-year CAGR——
10-year CAGR——

Debt Repayment history

USD · from the cash flow

Latest · FY2025
11.84M USD
Year-over-year change
-60.2%
4-year CAGR
-36.1%

Debt Repayment vs competitors

How HROW compares with its peers on the latest reported figures

  • Peers report in different currencies, so debt repayment is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +103.9% is the highest of 6, against a peer median of -29.3%.
  • Debt repayment amounts to 22.6% of revenue for HROW, versus a peer median of 2.0%.
HROW Competitors
Debt Repayment for HROW and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BLCOBausch + Lomb CorporationLTM Jun 2026$141.75M USD-51.5%-53.4%2.7%
HROWHarrow Health, Inc.LTM Mar 2026$60.73M USD+103.9%-28.0%22.6%
TTRXTurn Therapeutics Inc.LTM Mar 2026$6.72M USD———
OTLKOutlook Therapeutics, Inc.LTM Mar 2026$3.23M USD-1764.2%+9.5%970.3%
OCSOculis Holding AGLTM Mar 2026CHF 387K CHF+22.1%+32.9%76.8%
EYPTEyePoint Pharmaceuticals, Inc.LTM Mar 2026$99K USD-29.3%—1.3%
KODKodiak Sciences Inc.LTM Sep 2026$0 USD———
TARSTarsus Pharmaceuticals, Inc.LTM Sep 2026$0 USD+100.0%—0.0%
OCULOcular Therapeutix, Inc.LTM Mar 2026$0 USD——0.0%
Peer median (excluding HROW) —-29.3%+9.5%2.0%

Competitors are the stored peer set for HROW. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(18.01M)(14.09M)(24.41M)(17.48M)(5.14M)
Depreciation & Amortization2.4M3.67M12.34M14.54M19.68M
Deferred Income Tax00000
Stock-Based Compensation5.75M7.97M15.7M17.62M12.5M
Change in Working Capital(253K)(5.57M)(7.14M)(44.63M)185K
Accounts Receivables(1.83M)(1.86M)(30.34M)(80.23M)5.01M
Inventory(255K)(2.32M)(4.33M)165K(2.82M)
Accounts Payables1.73M933K31.8M37.5M(4.61M)
Other Working Capital103K(2.32M)(4.26M)(2.06M)2.6M
Other Non-Cash Items15.2M9.72M7.35M7.75M16.64M
Operating Cash Flow5.08M1.71M3.84M(22.2M)43.86M
Capital Expenditures(28.51M)(7.77M)(152.55M)(38.67M)(1.1M)
Acquisitions (Net)9.83M000(4.36M)
Purchases of Investments00000
Sales of Investments9.83M005.51M0
Other Investing Activities(36.55M)854K(151.09M)(37.08M)(215K)
Investing Cash Flow(18.69M)(1.74M)(152.55M)(33.16M)(5.46M)
Debt Repayment71.07M31.72M74.64M29.78M11.84M
Common Stock Issued022.66M64.52M0467K
Common Stock Repurchased00000
Dividends Paid(127K)0000
Other Financing Activities(19.12M)(234K)(12.63M)(1.25M)(25.04M)
Financing Cash Flow51.47M54.14M126.53M28.53M(12.72M)
Effect of Forex Changes00000
Net Change in Cash37.87M54.1M(22.19M)(26.84M)25.68M
Free Cash Flow(23.43M)(6.07M)(148.71M)(60.88M)42.76M

Harrow Health, Inc.

NASDAQ:HROW

Intrinsic Alpha fair value

Locked

Current Price

$32.16

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.